Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Prediction: 2 Stocks That Will Be Worth More Than IonQ 5 Years From Now

IonQ is the most famous quantum stock on the market, and it is worth $12.5 billion. One satellite imaging company and one nuclear start-up could both pass it by 2031.

Two companies have the potential to be worth more than IonQ in five years, according to a recent analysis. Planet Labs, a satellite imaging firm, has shown impressive growth and recently secured major defense and intelligence contracts. With a $5 billion market value, 58% revenue growth, and a path to profitability, Planet Labs only needs to double in value over the next five years to surpass IonQ's current valuation.

Currently, Planet Labs operates over 100 satellites and has a backlog of contracts that cover more than two years of revenue. Oklo, on the other hand, is a riskier investment but also has the potential to grow significantly. The company designs small fast-fission reactors and has signed a prepayment agreement with Meta Platforms for a 1.2-gigawatt campus in Ohio, which could become operational by 2030.

If Oklo successfully turns on its reactors and secures long-term contracts, it could be valued at $13 billion by 2031, making it worth more than IonQ. However, both companies face challenges, such as reliance on government budgets and potential debt, which could impact their growth trajectories. Investors should consider these factors before making investment decisions.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

  • Amgen reported $36.7B revenue in FY 2025, 10% growth, 21% net margin
  • Johnson & Johnson reported $94.2B revenue in FY 2025, 6% growth, 28.5% net margin
  • Johnson & Johnson has lower debt-to-equity ratio (0.6x) vs Amgen's 6.3x

More from Saturday 24 October →